Enterprise Data Management

Drugdevelopmentnowmovesatalgorithmicspeed,andyetthetruthisclear:AIistrustworthyonlywhenthedataandcontrolsbehinditare. Every model that estimates dose response, flags an adverse event, optimizes a batch record, or forecasts demand inherits the strengths and weaknesses of its inputs, lineage, and

A single pricing shift rippled across a retailer’s margins before anyone could explain why, a CFO demanded the origin and reasoning behind the change, and the operations team discovered the culprit was an autonomous agent acting on incomplete context. That kind of moment now defines enterprise AI

Sensitive data does not wait politely in line for a cloud connection, so the question is whether a vector database can meet sovereignty, latency, and governance demands while still delivering the fast, reliable retrieval that production AI pipelines require. That tension between control and speed

Clinical teams already sitting on terabytes of heterogeneous study data are finding that the difference between an on‑time submission and a costly protocol amendment increasingly hinges on how quickly patterns, outliers, and risks appear on a screen rather than in a spreadsheet, and that shift has

Drug pipelines rise or fall on decisions made with imperfect information, yet the signal hidden in clinical registries, regulatory filings, and conference disclosures has remained stubbornly hard to use at scale. That friction has distorted portfolio choices, delayed course corrections, and

Boardrooms demanded explainable AI long before chatbots charmed end users, and the gap between friendly prose and audited numbers left most pilots stranded in “demo limbo” where no one could sign off the results with confidence. Alteryx’s AI Insights Agent set out to close that gap by wiring Gemini